Dnth Holdings Corp. (DNTH) presented its clinical development strategy for claseprubart, a complement inhibitor designed to treat myasthenia gravis, CIDP and multifocal motor neuropathy. Chief Executive Marino Garcia outlined the drug's positioning as a first-line biologic option across the three indications at the 3rd Annual Guggenheim Healthcare Innovation Conference on November 9, 2026.
Dnth reported $1.2 billion in cash, which Garcia said funds operations and major clinical catalysts through 2030. The company holds 75% responder rates in CIDP Part A's first 40 patients, with enrollment now exceeding 80 patients. Part B of the CIDP trial is ahead of schedule, with data expected in 2025. The company expects Phase II results for myasthenia gravis and multifocal motor neuropathy in December, and Phase III data for generalized MG in the second half of 2028.
Garcia claimed claseprubart is seven times more potent than riliprubart and 38 times more potent than empasiprubart at the IC90 using standard assays. The drug is designed for once-monthly dosing in MG and once every two weeks in CIDP and MMN. Garcia said dosing takes five seconds and may allow room-temperature storage for up to four weeks pending confirmation.
Garcia addressed the competitive environment, noting that less than 20% of AChR-positive myasthenia gravis patients take biologics despite a decade of complement inhibitors and FcRn therapies being available. He said the recent approval of UPLIZNA validates the complement pathway but positioned claseprubart as having faster onset and more convenient dosing than weekly injections.
The MoMeNtum Phase II study for myasthenia gravis has 46 patients completed and targets 15 per arm. The MMN Phase II trial follows the same structure with about 15 patients per arm. Garcia said the MMN study is primarily focused on safety, adding there is "almost nothing" that would stop advancement to Phase III.
The company is advancing DNTH212 and DNTH312 as next-generation programs beyond claseprubart.